These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10929184)

  • 1. Histologic improvement of fibrosis in patients with hepatitis C and sustained response to interferon therapy.
    Bolaños-Meade J; López-Arvizu C
    Ann Intern Med; 2000 Aug; 133(4):312. PubMed ID: 10929184
    [No Abstract]   [Full Text] [Related]  

  • 2. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.
    Shiratori Y; Imazeki F; Moriyama M; Yano M; Arakawa Y; Yokosuka O; Kuroki T; Nishiguchi S; Sata M; Yamada G; Fujiyama S; Yoshida H; Omata M
    Ann Intern Med; 2000 Apr; 132(7):517-24. PubMed ID: 10744587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)].
    Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842
    [No Abstract]   [Full Text] [Related]  

  • 4. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of liver fibrosis in patients treated by interferon.
    Omata M
    Intern Med; 2004 Oct; 43(10):887-8. PubMed ID: 15575231
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possibility and significance of interferon therapy for liver cirrhosis type C].
    Iwabuchi S; Osada T
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):746-53. PubMed ID: 7563868
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C.
    Khokhar N; Niazi TK; Qureshi MO
    J Coll Physicians Surg Pak; 2013 Oct; 23(10):699-702. PubMed ID: 24112253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease stage of chronic hepatitis C assessed by both peritoneoscopic and histologic findings and its relationship with response to interferon therapy.
    Ohkawa K; Hayashi N; Yuki N; Kasahara A; Oshita M; Mochizuki K; Katayama K; Fusamoto H; Kato M; Masuzawa M; Yoshihara H; Mukuda T; Kamada T
    Gastrointest Endosc; 1997 Feb; 45(2):168-75. PubMed ID: 9041004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
    Everson GT; Balart L; Lee SS; Reindollar RW; Shiffman ML; Minuk GY; Pockros PJ; Govindarajan S; Lentz E; Heathcote EJ
    Aliment Pharmacol Ther; 2008 Apr; 27(7):542-51. PubMed ID: 18208570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluating the efficacy of interferon therapy on hepatitis C patients].
    Shiraha H; Iwasaki Y; Shiratori Y
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):489-92. PubMed ID: 15359847
    [No Abstract]   [Full Text] [Related]  

  • 12. Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.
    D'Ambrosio R; Degasperi E; Aghemo A; Fraquelli M; Lampertico P; Rumi MG; Facchetti F; Grassi E; Casazza G; Rosenberg W; Bedossa P; Colombo M
    PLoS One; 2016; 11(6):e0155967. PubMed ID: 27304619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Editorial commentary: Hepatitis C].
    Pár A
    Orv Hetil; 2015 May; 156(21):835. PubMed ID: 26038989
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
    Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
    Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with hepatitis C and cirrhosis.
    Wright TL
    Hepatology; 2002 Nov; 36(5 Suppl 1):S185-94. PubMed ID: 12407593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
    D'Ambrosio R; Aghemo A; Rumi MG; Primignani M; Dell'Era A; Lampertico P; Donato MF; De Nicola S; Prati GM; de Franchis R; Colombo M
    Antivir Ther; 2011; 16(5):677-84. PubMed ID: 21817189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of IL-28B polymorphism on outcome in patients with hepatitis C after liver transplantation.
    Neumann U
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):429-31. PubMed ID: 21780887
    [No Abstract]   [Full Text] [Related]  

  • 19. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.
    Xirouchakis E; Triantos C; Manousou P; Sigalas A; Calvaruso V; Corbani A; Leandro G; Patch D; Burroughs A
    J Viral Hepat; 2008 Oct; 15(10):699-709. PubMed ID: 18673428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.